Inside this issue

- EB '04 in Review
- AAHRPP Accreditation
- ASPET Committees for 2004-2005
- New England Pharmacologists Becomes Newest ASPET Regional Chapter
You can reach us at
www.aspet.org
info@aspet.org
phone 301-634-7060
fax 301-634-7061
ASPET met with Experimental Biology ’04, April 17-21, 2004, in Washington D.C. The major portion of the meeting was held in the new Washington, D.C. convention center, an imposing building of concrete and glass (see cover). Washington emerged from an extended period of cold and rain to host EB with warm and sunny days. The Opening Reception was held on the top floor of the new convention center where full-length windows provided a 180° view of the downtown landmarks. Pictures from many of the division activities can be found on the web sites for Cardiovascular Pharmacology, Molecular Pharmacology, and Neuropharmacology. (http://www.aspet.org/public/divisions/cardiovascular/news.htm, http://www.aspet.org/public/divisions/molpharm/EB2004pix.htm, and http://www.aspet.org/public/divisions/neuropharm/news.htm). Next year ASPET will meet with EB ’05 in San Diego, CA. Note that the meeting is unusually early next year, starting April 2 and going through April 6.

Left: B.B. Brodie Award winner Thomas L. Poulos with his family after the Awards Ceremony.

Right: Pharmacia-ASPET Award winner Philip Needleman with ASPET President David Bylund at the Awards Ceremony.

Left: Goodman and Gilman Award in Drug Receptor Pharmacology Award winner Lee Limbird with her husband and ASPET President David Bylund.

Right: P.B. Dews Award winner Joseph V. Brady receives his award from ASPET President David Bylund.

Left: J. J. Abel Award winner David Siderovsky with his family and ASPET President David Bylund.
Past Presidents Allan Conney (l), Palmer Taylor, and William Dewey (r) confer at one of the many social events.

Division for Behavioral Pharmacology Best Paper Award Winners
L to R: Graduate Student Best Paper winner, Sunmee Wee; Division Chair, Jonathan Katz; Division Past Secretary/Treasurer, Carol Paronis; and Postdoctoral Best Paper winner, Rjeev Desai.

Division for Systems and Integrative Pharmacology Best Paper Award Winner, John Dubinion, Jr, is flanked by Division Chair, George Christ, on the left and Secretary/Treasurer-Elect, Andre Dray.

Division for Drug Discovery, Drug Development & Regulatory Affairs Young Investigator Award Winners; L to R: Division Chair, Willie Caldwell; Thomas Stover; Wu Yong; Dinesh Srinivasan; and Division Secretary/Treasurer, Ron Dundore.

Left: Philip Needleman accepts the Pharmacia-ASPET Award in Experimental Therapeutics.

Right: President-Elect Stephen Holtzman presents outgoing President David Bylund with a plaque and the thanks of the Society at the Business Meeting on Sunday evening.
AAHRPP Accreditation Taking Hold

By Marjorie A. Speers, Ph.D., Executive Director

The Association for the Accreditation of Human Research Protection Programs—founded in 2001 as a means for organizations to demonstrate their commitment to protecting research participants—is making progress in its efforts to create a voluntary, peer-reviewed, and educational accreditation program:

- Since May 2003, accreditation has been awarded to six organizations: Baylor Research Institute, Catholic Medical Center, Hunter Holmes McGuire VA Medical Center, New England Institutional Review Board, The University of Iowa, and Western Institutional Review Board. AAHRPP purposefully designed its program and accreditation standards to be applicable in the diverse settings where human research occurs.
- Many institutions are engaged in some stage of the accreditation process: reviewing policies and procedures, conducting the self-assessment, preparing for a site visit, or responding to the AAHRPP site visit report.
- The Department of Energy recently announced that its laboratories that conduct significant amounts of human research will seek accreditation in 2004.
- In September, the Centers for Disease Control and Prevention awarded AAHRPP a three-year grant to assess the role of accreditation in enhancing the protection of participants in public health research. Pilot measures will be developed and implemented in several locations, and then refined and made available to public health research partners to document and evaluate the impact of accreditation.
- The Secretary’s Advisory Commission on Human Research Protection issued a preliminary report on accreditation in December: “The [Accreditation] Subcommittee supports the concept of accreditation of Human Research Protection Programs (HRPP’s) for the protection of human subjects in research. Accreditation promises to be a useful mechanism for all organizations involved in human research that, like education and certification, leads to self-improvement of systems and outcomes.” The subcommittee interviewed institutional officials from two AAHRPP-accredited organizations in its deliberations.

All of these activities indicate that accreditation is beginning to fulfill its promise as an effective mechanism for insuring that research organizations comply with federal regulations governing research, but more importantly, that they maintain comprehensive human research protection programs.

AAHRPP was founded three years ago by FASEB and six other national organizations in an environment of grave concern; because of the shutdowns of major research programs by the federal government, research programs overall were being intensely scrutinized by lawmakers and by the media. Congressional bills to regulate research more rigorously were introduced in both the House and the Senate.

AAHRPP came together as a means for self-regulation by the research community. If research organizations were willing to subject themselves to a rigorous process of peer review and education, then further regulation could be avoided. Although high-profile research incidents have not occurred in several years, there is still interest among legislators in further regulating this area, as demonstrated by Rep. Diana DeGette’s introduction of a bill in the House last November.

We welcome your questions about any aspect of the AAHRPP accreditation program.

Information: Marjorie Speers, mspeers@aahrpp.org, (202) 783-1112; Todd Bentsen, tbentsen@aahrpp.org, (202) 783-8133.

For more information on AAHRPP and what accreditation means to your research program and your institution, visit the web site.

http://www.aahrpp.org
COUNCIL
Stephen G. Holtzman (2006), President
James E. Barrett (2007), President-Elect
David B. Bylund (2005), Past President
James R. Halpert (2006), Secretary/Treasurer
Patricia K. Sonsalla (2007), Secretary/Treasurer-Elect
Cinda Helke (2005), Past Secretary/Treasurer
Kim A. Neve (2005), Councilor
Donald C. McMillan (2006), Councilor
Ronald N. Hines (2007), Councilor
Brian M. Cox (2005), Chair, BPT
Lynn Wecker (2005), Chair, Program Committee
Christine K. Carrico, ex officio

FINANCE COMMITTEE
James Halpert (2006), Chair
Nancy Ator (2007)
James Barrett (2005)
Joe Beavo (2007)
Patricia K. Sonsalla (2007)
Brian M. Cox (2005)
Charles O. Rutledge (2007)
Christine K. Carrico, ex officio

Investment Subcommittee
Charles O. Rutledge (2007), Chair
Daniel L. Azarnoff (2005)
James R. Halpert (2006)
Patricia K. Sonsalla (2007)
Stephen G. Holtzman, ex officio
Christine K. Carrico, ex officio

PROGRAM COMMITTEE
Lynn Wecker (2005), Chair
Darrell R. Abernethy (2006), Clinical Pharmacology
Michael Babich (2006)
Dale L. Birkle (2006)
George J. Christ (2005), Systems & Integrative Pharmacology
Michael R. Franklin (2005), Drug Metabolism
Jonathan L. Katz (2005), Behavioral Pharmacology
Suzanne G. Laychock (2007)
Terrence Monks (2005), Toxicology
David Port (2005), Molecular Pharmacology
Nancy J. Rusch (2006), Cardiovascular Pharmacology
Jack W. Strandhoy (2005), Pharmacology Education
Joanne Trejo (2007)
Benjamin R. Yerxa (2005), Drug Discovery, Drug Development & Regulatory Affairs
Jeffrey S. Fedan, Short Course Committee
Christine K. Carrico, ex officio

BOARD OF PUBLICATIONS TRUSTEES (BPT)
Brian M. Cox (2005), Chair
Lorraine Gudas (2006)
Rick Neubig (2006)
Darryle D. Schoepf (2005)
Darrell R. Abernethy (2004), Editor
Paul I. Insel (2005), Editor
Sue P. Duckles (2004), MI Editorial Advisory Board
Rick G. Schnellman (2006), Editor
James R. Halpert (2005), Editor
Christine K. Carrico, ex officio
Richard Dodenhoff, Staff Liaison

2004 NOMINATING COMMITTEE
Paul F. Hollenberg, Chair
David Flockhart (Clinical Pharmacology)
Thomas A. Kocarek (Drug Metabolism)
Edwin K. Jackson (Cardiovascular Pharmacology)
Kathryn E. Meier (Molecular Pharmacology)
Carol A. Paronis (Behavioral Pharmacology)
Lynn Wecker, Program Committee, ex officio
Christine Carrico, ASPET, ex officio

2005 NOMINATING COMMITTEE
David Bylund, Chair
Andre Dray (Systems and Integrative Pharmacology)
Ronald L. Dundore (Drug Discovery, Development & Regulatory Affairs)
L. Charles Murrin (Neuropharmacology)
Joan B. Tarloff (Toxicology)
Jordan Warnick (Pharmacology Education)
Lynn Wecker, Program Committee, ex officio
Christine Carrico, ASPET, ex officio

Program Committee
Jeffrey S. Fedan (2006), Chair
William T. Gerthoffer (2006)
Deborah L. Lewis (2005)
Kathryn E. Meier (2006)
Lynn Wecker (2005), Program Committee
Christine K. Carrico, Staff Liaison
Committees Established by Resolution of Council

CENTENNIAL COMMITTEE
William L. Dewey, Chair
William W. Fleming
David J. Jones
Suzanne G. Laychock
Michael R. Vasko
Stephanie W. Watts
Christine K. Carrico, ex officio
James S. Bernstein, staff liaison

COMMITTEE ON COMMITTEES
James E. Barrett (2007), Chair
David B. Bylund (2005)
Christine K. Carrico

COMMITTEE ON GRADUATE RECRUITMENT AND EDUCATION
Barbara S. Beckman (2005), Chair
Carol Bender (2005)
Edward Bilsky (2005)
Raymond R. Mattingly (2006)
Jose F. Rodriguez (2005)
Myron L. Toews (2006)
Stephanie W. Watts (2005)
Paula Witt-Enderby (2005)
Jeffrey M. Brown (2006), Student/Fellow Representative
Paul Setlak (2006), Student/Fellow Representative
Margarita Dubocovich, Committee on Minorities
Kim A. Neve, Council Liaison
Christine K. Carrico, Staff Liaison

LONG RANGE PLANNING COMMITTEE
Paul F. Hollenberg (2005), Chair
James E. Barrett (2007)
David B. Bylund (2005)
Brian M. Cox (2007)
Margarita L. Dubocovich (2005)
Ronald N. Hines (2007)
Donald C. McMillan (2006)
Kim A. Neve (2005)
Christine K. Carrico, ex officio

COMMITTEE ON MINORITIES
Margarita L. Dubocovich (2005), Chair
Anindya Bhattacharya (2007)
Martha Davila-Garcia (2006)
Richard De La Garza (2005)
Julie G. Hensler (2007)
Gonzalo Torres (2007)
Tara Macey (2006), Student/Fellow Representative
Joan M. Lakoski (2005), WIP Liaison
Barbara Beckman (2005), Committee on Graduate Recruitment and Education Liaison
Patricia K. Sonsalla, Council Liaison
Christine K. Carrico, Staff Liaison

COMMITTEE ON PUBLIC AFFAIRS
Gerald J. Schaefer (2007), Chair
Henry R. Besch (2007)
Steven J. Dworkin (2007)
Edward D. French (2007)
David J. Jones (2006)
Mariana Morris (2006)
James D. Potter (2007)
David P. Westfall (2006)
David B. Bylund (2005), Council Liaison
James S. Bernstein, Staff Liaison

SCIENTIFIC COUNCIL
David B. Bylund (2005), Chair
Raymond J. Dingledine (2005)
Linda Dykstra (2006)
Ronald Dundore (2006)
Brian B. Hoffman (2005)
Michael Kuhar (2005)
Ismail Laher (2006)
Harrihara Mehendale (2006)
Mariana Morris (2005)
Timothy Tracy (2006)
Steven G. Holtzman, ex officio
Lynn Wecker, ex officio
Christine K. Carrico, ex officio

COMMITTEE ON WOMEN IN PHARMACOLOGY
Joan M. Lakoski (2005), Chair
Nancy J. Brown (2007)
Jennifer M. McCafferty (2005)
Susan Steinberg (2007)
Joanne Chan (2006), Student/Fellow Representative
Margarita Dubocovich (2005), Minorities Committee
Patricia K. Sonsalla, Council Liaison
Christine K. Carrico, Staff Liaison

ASPET AWARDS COMMITTEES
B. B. Brodie Award in Drug Metabolism Committee
Paul R. Ortiz de Montellano (2005), Chair
M. W. Anders (2005)
Eric F. Johnson (2007)
Bettie Sue S. Masters (2005)
**FASEB Directory**

ASPET will not be providing the printed FASEB Directory to its members this year. You will be able to order the printed directory for $35. This is a savings of more than 40% over the normal price.

Because many more people indicated they intended to purchase the directory than actually did, we will no longer be taking advance orders.

We will send out a separate order form this summer which you must return with payment, or you can fill out the form on page 45 of this issue of *The Pharmacologist*.
YES!

I would like to order a copy of the printed

2004-2005 FASEB Directory
for the ASPET member price of $35.

Name:
Mailing Address:

City:          State:   Postal Code:

Country:

PAYMENT METHOD

☐ Enclosed is my check (in US $) for $35 made payable to ASPET.

☐ Please bill my credit card for $35.

Credit Card: ☐ VISA ☐ MasterCard ☐ American Express

Account Number: Expiration Date (mm/yy): Bank Code:

Signature (if submitted in hard copy)

Name as it appears on the credit card:

I give ASPET the authority to charge my credit card for the amount indicated on this form.
2005 Subscription Prices Set

The Board of Publications Trustees has set the 2005 subscription prices for ASPET’s five journals. The annual subscription rate for *JPET*, *Pharmacological Reviews*, *Molecular Pharmacology*, and *Drug Metabolism and Disposition* will increase by 8% for print with online access. The price for *Molecular Interventions* will increase by 4%. Online-only access will be set at 90% of the print-with-online price.

In setting the 2005 prices, the BPT took into account the budget restrictions of college and university libraries, the need for the Society to at least at break even in its publication program, and the added value to subscriptions from the inclusion of soon-to-be-digitized back issues (see related below).

Prices for member print subscriptions will increase by 6%. Members have access to all of ASPET’s online journals as a benefit of membership. The back-issue collection will be included with member access.

Back Issues to be Digitized

Every issue of every ASPET journal will be available online by early 2005. The Board of Publications Trustees approved a project to digitize the back issues of ASPET’s journals so that the entire archive from volume 1, issue 1 of each journal will be available electronically.

HighWire Press, which hosts the Society’s online journals, found a benefactor to provide free scanning of back issues. In addition, HighWire is waiving its management fee for this project. Other costs remain, but the price of scanning (approximately $300,000) was the largest barrier to making back issues available. By increasing subscription prices slightly more than normal, ASPET will be able to cover the costs of the project and provide members and subscribers with this valuable resource.

Last summer, ASPET participated in a pilot scanning project to test the equipment that will be used for scanning. The pilot program was a success, so the benefactor (an organization that wishes to remain anonymous for the time being) is moving forward with digitization of entire collections of journals. There are approximately 280,000 pages of back issues to digitize. *JPET* began publication in 1909, *Pharmacological Reviews* in 1949, *Molecular Pharmacology* in 1965, and *Drug Metabolism and Disposition* in 1973. Scanning will begin this summer, and the materials are expected to be available online by early 2005.

In anticipation of the project, the ASPET Journals Department began collecting back issues in May 2003. The bulk of the issues came from a medical society library in New York City that was in the process of closing. Several ASPET members generously donated personal copies to fill the gaps in that collection. They include Jonathan Katz, Ken Harden, Rick Neubig, David Moody, Terry Monks, and Alan Buckpitt. Without their help, the entire archive would not be available.

The archival articles will be indexed by Google. The title, byline, and abstract of every article will be searchable. The archive is expected to provide complete issues, including tables of contents, editorial boards, letters to the editor, book reviews, and any other item published in the issue. By providing complete issues, this electronic archive will allow libraries to dispose of print archives. Many large libraries have moved very old issues to off-site storage, making them difficult and expensive to retrieve. The online availability of these materials will save money and make available generations of research that was increasingly overlooked because it was too difficult to access.

The debut of the online archives will be announced via email and on each journal’s website.

Fast Forward for MolPharm and DMD

The publish-ahead-of-print feature, *Fast Forward*, went live for *Molecular Pharmacology* on May 21 and on June 9 for *Drug Metabolism and Disposition* by the time this issue of *The Pharmacologist* is published. As we have been doing for *JPET*, manuscripts are published online as soon as possible after they are accepted. In most cases, this is within a day or two. *Fast Forward* articles are published online approximately 8 to 12 weeks prior to publication in an issue.
There is a link on each journal’s homepage to the Fast Forward articles. They are arranged by date of publication, with the most recent articles at the top of the page. Once an article appears in an issue, it is removed from the Fast Forward list. However, the Fast Forward version remains available through a link in the article’s content box, which can be found in the upper right corner at the beginning of the HTML version.

All Fast Forward papers are considered officially published. The date of publication is noted under the article’s title. Articles are assigned a Digital Object Identifier (DOI), which can be used to cite the article in place of a volume, issue, and page numbers. The DOI remains with the article forever and never changes, making it a reliable citation tool. All of ASPET’s DOIs are deposited with CrossRef, which provides linking among hundreds of publishers and thousands of journals.

Those using the alerting features of the online journals will soon be able to include alerts for new Fast Forward articles. Users will have the option of receiving alerts daily or weekly. Instructions will be emailed to all members when this feature is operational.

**Molecular Interventions Now Indexed**

ASPET’s newest journal, Molecular Intervention, is now indexed by PubMed/Medline/ ISI Science Citation Index, and the Elsevier Bibliographic Databases. Indexing is now complete back to the first issue of MI, in April of 2001. Molecular Interventions is published bimonthly and is provided to all ASPET members. If you would be interested in contributing to an upcoming issue of MI, please contact the Editor, Harry Smith, at hsmith@aspet.org or 301-634-7790.

---

In 2005, Americans are expected to spend $92 billion on international travel. This amount would fund all of the health research in the United States for one year.

From: Research!America and the U.S. Department of Commerce, International Trade Administration, Office of Travel and Tourism Industries and Bureau of Economic Analysis, April 2004
ASPET-Merck Postdoctoral Fellowships in Integrative Pharmacology

This year’s ASPET-Merck Awards will support one postdoctoral fellowship to support training in neuroscience with an emphasis in neurodegeneration/neurogenesis. Additional details can be found on the ASPET web site at: www.aspet.org/public/merck_fellowships/guidelines.html

NIGMS RFA to Support Training of Integrative Whole Organ Biologists

NIGMS issued a request for applications for education projects that will introduce students to the knowledge and skills needed for studies of integrative organ system and whole organism biological responses to drugs and other physiological perturbations. ASPET members interested in submitting proposals might consider contacting Jim Bernstein at 301-634-7062 to determine if there are other local/regional institutions considering submitting proposals. Although only one institution may serve as the applicant organization, a coordinated institutional response is necessary. View: http://grants2.nih.gov/grants/guide/rfa-files/RFA-GM-05-006.html

Accreditation of Human Research Protection Programs

The Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP) protects the rights and welfare of research participants by fostering and advancing the ethical and professional conduct of persons and organizations that engage in research with human participants. AAHRPP achieves its mission by using an accreditation process based on self-assessment, peer review, and education. ASPET members are encouraged to bring to their institutions attention the value of AAHRPP accreditation programs. AAHRPP Executive Director Marjorie Speers talks about AAHRPP in an article on page 41 of this issue. For additional information visit their web site at: www.aahrpp.org

FASEB Seeks Expertise on BMBL

FASEB is preparing comments in response to a solicitation from OSTP and CDC on revision of the “Biosafety in Biological and Microbiological Laboratories” guide (BMBL). FASEB is seeking help from qualified researchers whose expertise can aid in preparing thoughtful and substantive comments. Nearly all biological laboratories are involved in BMBL compliance, but this issue may be of particular interest to those working with Select Agents or microorganisms. If you are interested or would like more information on how you might help, please contact Carrie Golash at FASEB Public Affairs Office at tel: 301/634-7650.

Rand Analysis Shows Federal R&D Dominated By Medical School Research Investment

A Rand study indicates that research at medical schools has benefited most from the doubling of the National Institutes of Health’s budget. RAND reports that in 2002, 45% of all federal R&D funding provided to universities and colleges by any federal agency went to the nation’s 126 medical schools. View a summary of the Rand report at: http://www.rand.org/publications/MR/MR1824/

June NIH Summit Workshop on Predictive Drug Toxicology

As part of the Molecular Libraries Initiative of the NIH Roadmap, this workshop will address our current understanding of drug-induced toxicities; discuss new procedures that may improve absorption, distribution, metabolism, excretion and toxicology (ADMET) analysis; and identify new techniques and research to prevent the selection of compounds that will fail in clinical testing. In this workshop, researchers from academia, the pharmaceutical industry, and the FDA will describe areas in which additional research is needed to improve predictive analyses and discuss what new science may be needed to improve preclinical testing to reduce the failure rate of drug candidates. Information at: http://www.nihsummitworkshop.com
Funding Opportunity

Medication Discovery Using Rat Models of Relapse to Drug Self-Administration (NOT-DA-04-027)
National Institute on Drug Abuse

New Publication on Basic Research


Statement on Visa Problems Harming Science

A position statement produced by several scientific, higher-ed and engineering organizations notes the unintended consequences of the federal government’s visa policies. The statement can be read at: http://www.aaas.org/news/releases/2004/0512visa.pdf.

NIH Conflict of Interest Congressional Hearings

The House Energy and Commerce Subcommittee on Oversight and Investigations continued hearings on NIH conflicts of interest. To read witness testimony view: http://energycommerce.house.gov/108/Hearings/05182004hearing1275/hearing.htm

ASPET-Merck Postdoctoral Fellowship in Integrative Pharmacology

The major goal of this program is to increase the number of well-trained scientists with expertise in pharmacology and integrative biology. The majority of the Fellowship will be spent in the laboratory of the academic supervisor/mentor with no less than six months spent in the laboratories of the award sponsors, Merck Research Laboratories, San Diego. Fellowships are for post-doctoral training. The academic institution must be in the United States.

One award in neurodegeneration/neurogenesis will be made in 2004. The fellowship term is 3 years, subject to annual performance review, and provides the following per annum funding:

- $42,000 stipend
- $ 3,000 travel expenses
- $10,000 institutional grant

During the tenure at the Merck laboratory, additional support up to $10,000 will be available to offset expenses related to the temporary relocation.

Application deadline is September 7, 2004.

For additional information, go to www.aspet.org/public/merck_fellowships/guidelines.html
Call for Award Nominations For 2005

THE TORALD SOLLMANN AWARD
IN PHARMACOLOGY INVESTIGATION & EDUCATION

The Torald Sollmann Award in Pharmacology was established to commemorate the pioneer work of Dr. Torald Sollmann in the fields of pharmacological investigation and education. Sponsored by Wyeth Research, the Torald Sollmann Award is presented biennially in odd years for significant contributions over many years to the advancement and extension of knowledge in the field of pharmacology. The award consists of an honorarium of $3,500, a medal, and travel expenses for the winner and spouse to the annual meeting. The formal presentation of this biennial award and medal will be made at the annual meeting of ASPET. The recipient will be invited by the President of the Society to deliver a Sollmann Oration to the membership that may be published in an appropriate ASPET journal.

There are no restrictions on nominees for this award. However, a nomination must be made by a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), and no member may nominate more than one candidate in a year. The award shall be made on the basis of originality and uniqueness of accomplishments throughout a long career distinguished by sustained, significant contributions to education, research, and service in pharmacology. Selection of the recipient will be made by the Torald Sollmann Award Committee, consisting of five present and former members of the ASPET Council, with the Senior Councilor serving as chair.

Nominations shall be accompanied by six (6) copies of each of the following:

1. **No more than** five letters from nominators describing the contributions to pharmacology of the candidate that make him/her eligible for this Award, listing major contributions.
2. Brief biographical sketch of the candidate.
3. Candidate’s curriculum vitae and bibliography.

Nominations for the 2005 Award must be received no later than **September 15, 2004** by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

**Winners of the Torald Sollmann Award**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1961</td>
<td>Otto Krayer</td>
</tr>
<tr>
<td>1963</td>
<td>Bernard B. Brodie</td>
</tr>
<tr>
<td>1966</td>
<td>Arnold D. Welch</td>
</tr>
<tr>
<td>1969</td>
<td>Earl W. Sutherland, Jr.</td>
</tr>
<tr>
<td>1973</td>
<td>Julius Axelrod</td>
</tr>
<tr>
<td>1975</td>
<td>Sidney Udenfriend</td>
</tr>
<tr>
<td>1981</td>
<td>Avram Goldstein</td>
</tr>
<tr>
<td>1984</td>
<td>K. K. Chen</td>
</tr>
<tr>
<td>1986</td>
<td>Walter K. Riker</td>
</tr>
<tr>
<td>1988</td>
<td>James A. Bain</td>
</tr>
<tr>
<td>1990</td>
<td>George B. Koelle</td>
</tr>
<tr>
<td>1992</td>
<td>E. Leong Way</td>
</tr>
<tr>
<td>1995</td>
<td>Theodore M. Brody</td>
</tr>
<tr>
<td>1997</td>
<td>Alfred G. Gilman</td>
</tr>
<tr>
<td>1999</td>
<td>William W. Fleming</td>
</tr>
<tr>
<td>2001</td>
<td>Benedict R. Lucchesi</td>
</tr>
<tr>
<td>2003</td>
<td>Palmer W. Taylor</td>
</tr>
</tbody>
</table>

**JOHN J. ABEL AWARD**

The John J. Abel Award in Pharmacology, supported by Eli Lilly and Company, was established to stimulate fundamental research in pharmacology and experimental therapeutics by young investigators. The annual Award consists of $2,500, a bronze medal, and travel expenses for the winner and spouse to the award ceremony at the annual meeting of ASPET.

Nominees for this award shall not have passed their **thirty-ninth birthday on April 30** of the year of the Award. The candidate need not be a member of the Society; however, a nomination must be made by an ASPET member, and no member may nominate more than one candidate a year. The Award shall be made for original, outstanding research in the field of pharmacology and/or experimental therapeutics. Independence of thought, originality of approach, clarity and excellence of data presentation are important criteria. Candidates shall not be judged in comparison with the work of more mature and experienced investigators. Quality rather than the number of contributions shall be emphasized. It shall be the responsibility of the sponsor to make clear the contribution of the candidate to any jointly authored reprints and manuscripts and the originality and independence of the candidate’s research. Selection will be made by the J.J. Abel Award Committee, appointed by the President of ASPET.
CALL FOR AWARD NOMINATIONS FOR 2005

Nominations shall be accompanied by six (6) copies of each of the following:
1. Summary that describes the importance of the candidate’s work.
2. Each of six published articles or manuscripts accepted for publication that are a representation of the candidate’s work.
3. Brief biographical sketch of the candidate.
4. Candidate’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

Winners of the John J. Abel Award

1947 George Sayers 1966 Lewis S. Schanker 1985 P. Michael Conn
1948 J. Garrott Allen 1967 Frank S. LaBella 1986 Gordon M. Ringold
1949 Mark Nickerson 1968 Richard J. Wurtman 1987 Lee E. Limbird
1953 Herbert L. Borison 1972 Pedro Cuatrecasas 1991 Terry D. Reisine
1957 Dixon M. Woodbury 1976 Alan P. Poland 1995 Thomas M. Michel
1963 Steven E. Mayer 1982 Theodore A. Slotkin 2002 Steven A. Kliewer

THE PHARMACIA-ASPET AWARD IN EXPERIMENTAL THERAPEUTICS

The Pharmacia-ASPET Award in Experimental Therapeutics is given annually to recognize and stimulate outstanding research in pharmacology and experimental therapeutics—basic laboratory or clinical research that has had, or potentially will have, a major impact on the pharmacological treatment of disease. The award is supported in perpetuity by a gift from Pharmacia. The winner will receive a $2,500 honorarium, a bronze medal, and travel expenses for the winner and spouse to the award ceremony at the ASPET annual meeting.

There are no restrictions on nominees for this award. The Award shall be made on the basis of published reprints, manuscripts ready for publication, and a two-page summary. Selection will be made by the Pharmacia-ASPET Award Committee, appointed by the President of ASPET.

Nominations shall be accompanied by six (6) copies of each of the following:
1. Two (2)-page summary that details the importance of the candidate’s work.
2. Each of six articles published or ready for publication by the candidate that have direct bearing on the Award.
3. Brief biographical sketch of the candidate.
4. Candidate’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.
CALL FOR AWARD NOMINATIONS FOR 2005

Winners of the ASPET Award for Experimental Therapeutics

1969 John A. Oates
1970 Joseph R. Bertino
1971 Elliot S. Vesell
1972 Francois M. Abboud
1973 Dean T. Mason
1974 Leon I. Goldberg
1975 Mackenzie Walser
1976 Louis Lasagna
1977 Allan H. Conney
1978 Attallah Kappas
1979 Sydney Spector
1980 Sanford M. Rosenthal
1981 David G. Shand
1982 William H. Prusoff
1983 Marcus M. Reidenberg
1984 Sir James Black
1985 Louis Lemberger
1986 Alan C. Sartorelli
1987 Albrecht Fleckenstein
1988 Jean-Francois Borel
1989 Benedict R. Lucchesi
1990 Albert Sjoerdsma
1991 Theophile Godfraind
1992 James W. Fisher
1993 V. Craig Jordan
1994 Susan B. Horwitz
1995 Henry I. Yamamura
1996 Robert F. Furchgott
1997 Michael M. Gottesman
1998 Phil Skolnick
1999 Yung-Chi Cheng
2000 Saloman Z. Langer
2001 George R. Breese

Became Pharmacia-ASPET Award in Experimental Therapeutics

EPILEPSY RESEARCH AWARD FOR OUTSTANDING CONTRIBUTIONS TO THE PHARMACOLOGY OF ANTIEPILEPTIC DRUGS

The Epilepsy Award is sponsored by The International League Against Epilepsy (ILAE) and donated by Pfizer for the purpose of recognizing and stimulating outstanding research leading to better clinical control of epileptic seizures. This research may include the basic screening and testing of new therapeutic agents, studies on mechanisms of action, metabolic disposition, pharmacokinetics, and clinical pharmacology studies. This Award, presented biennially in odd years, consists of an honorarium of $2,000, a Certification of Citation, and travel expenses to the awards ceremony at the ASPET annual meeting.

Nominees for the 2005 award must be actively engaged in the research for which the Award is made, and primary emphasis will be placed upon work accomplished in the five-year period prior to the Award. Nominations for the Award may be submitted by members of any recognized scientific association, domestic or foreign. Selection of an awardee will be made biennially by the Epilepsy Award Committee appointed by the President of ASPET, with representation of ILAE.

Nominations shall be accompanied by six (6) copies of each of the following:
1. Summary describing the nominee’s major achievements.
2. Nominee’s six most significant papers, including manuscripts accepted for publication.
3. Brief biographical sketch of the candidate.
4. Nominee’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

Winners of the Epilepsy Award

1978 Alan Richens
1979 Paolo L. Morselli
1980 Dixon M. Woodbury
1981 James A. Ferrendelli
1982 Ewart A. Swinyard
1983 Arthur Camerman
1984 Phillip C. Jobe
1985 Robert J. DeLorenzo
1986 Robert L. Macdonald
1987 James O. McNamara
1988 Harvey J. Kupferberg
1989 Frank C. Tortella
1990 Robert Naquet
1991 Raymond Dillydine
1992 O. Carter Snead III
1993 Michael A. Rogawski
1994 Karen N. Gale
1995 Marc A. Dichter
1996 Robert Sloviter
2001 Wolfgang Löscher
2002 Darryle D. Schoepp
2003 William C. DeGroat
2004 Philip Needleman
The ASPET Division for Drug Metabolism presented its Graduate Student and Post-Doctoral Best Paper Awards at the Experimental Biology 2004 meeting in Washington, D.C., April 17-21, 2004. The award winners were as follows:

**Graduate Student Category**

First prize: **Yen Weng**, Department of Environmental Health and Toxicology, Wadsworth Center, School of Public Health, SUNY at Albany (Supervisor: Xinxin Ding), for the poster entitled “Microarray analysis of hepatic gene expression in liver-specific NADPH-cytochrome P450 reductase (Cpr)-knockout and global Cpr-knockdown mouse models.”

Second prize: **Tiangan Li**, Department of Biochemistry and Molecular Pathology, Northern Ohio Universities College of Medicine (Supervisor: John Chiang), for the poster entitled “Lithocholic acid (LCA) inhibits human cholesterol 7-hydroxylase transcription via pregnane X receptor (PXR)-mediated pathway.”

**Post-Doctoral Category**

First prize: **Badanthadka Murali**, Department of Toxicology, University of Louisiana at Monroe (Supervisor: Harihara Mehendale), for the poster entitled “Resistance of F344 rats to chlordecone-potentiated CCl₄ hepatotoxicity and lethality is age-dependent.” As part of this award, Dr. Murali is being offered a travel award to support attendance at next year’s Experimental Biology meeting in San Diego, where he is invited to participate in the Drug Metabolism Division Executive Committee Meeting.

Second prize: **Cheng Fang**, Wadsworth Center, New York State Department of Health (Supervisor: Xinxin Ding), for the poster entitled “Preparation and initial characterization of a transgenic mouse model with forebrain-specific knockout of the NADPH-cytochrome P450 reductase (Cpr) gene.”

Plans are underway to upgrade the Drug Metabolism Division/Toxicology Division joint mixer at next year’s Experimental Biology meeting, both by holding the event in a larger room and by using it as an additional forum for the winners to display their presentations.
New Members

REGULAR MEMBERS

Amin, Jahanshah, University of South Florida, Dept of Pharmacology
Birdsall, Nigel, Nat Inst for Medical Research, Div of Physical Biochemistry
Blumer, Kendall, Washington University School of Medicine, Dept of Cell Biology and Physiology
Bockaert, Joel, UPR CNRS 2580 - CCIP, 141 Rue De La Cardonille
Bradford, Peter, SUNY School of Medicine, Dept of Pharmacology & Toxicology
Brandt, Michael, Wyeth Research, Dept Neuroscience Discovery Research
Buhler, Amber, University of Iowa, Dept of Pharmacology
Buisson, Bruno, TROPHOS, Dept of Pharmacology & Toxicology
Caba, Ebru, University of Connecticut, Dept of Pharmaceutical Sciences & Neuroscience
Canatan, Halit, Kuwait University Faculty of Medicine, Dept of Pharmacology & Toxicology
Danaceau, Jonathan, University of Utah, Center for Human Toxicology
Das, Biswadeep, Manipal College of Medical Sciences, Dept of Pharmacology
Dzimiri, Nduna, King Faisal Spec Hospital, MBC-03-05, BMR Dept
Fink, George, Mental Health Research Institute, 155 Oak Street, Parkville
Forkert, Poh-Gek, Queen's University, Dept of Anatomy & Cell Biology
Hernandez, Yvonne, Georgetown University Medical Center, Dept of Pharmacology
Hill, Stephen, Queens's Medical Centre, Institute of Cell Signalling, Med Sch
Jacobson, Myron, University of Arizona, Arizona Cancer Ctr
Johnston, Richard, Harvard School of Public Health, Dept Environmental Hlth
Kleiner, Heather, Louisiana State University HSC, Dept of Pharmacology & Therapeutics
Korthuis, Ronald, University of Missouri, Dept of Medical Pharmacology & Physiology
Li, Shuang, University of Washington, Dept of Pharmacology
Li, Qian, University of Texas, Medical Branch, Dept of Psychiatry and Behavioral Sci
Li, Ningjun, Medical College of Wisconsin, Dept of Pharmacology & Toxicology
Liu, Xiaojing, University of Tennessee HSC, Dept of Pharmacology
Mattison, Donald, NIH, NICHD, Center for Rsch for Mothers and Children
Messing, Robert, University of California, E. Gallo Clinic and Rsch Center
Middlemas, David, University of Nebraska, Dept of Pharmacology
Murphy, Niall, Riken Brain Science Institute, Neuraol Circuit Mechanisms Rsch Group
Nothacker, Hans-Peter, University of California, Dept of Pharmacology
Pacher, Pal, NIH/NIAAA, Section of Neuroendocrinology
Pan, Hui-Lin, Penn State University College of Med, Dept of Anesthesiology
Petroski, Robert, Neurocrine Biosciences, 10555 Science Center Drive
Porzio, Stefano, Inpharzam Ricerche SA, Pharmacokinetic and Toxicology
Sengupta, Shiladitya, MIT, Biological Engineering Division
Smith, Kirsten, Walter Reed Army Institute of Rsch, Drug Development
Sorensen, Scott, GlaxoSmithKline, High Throughput Biology
Spigelman, Igor, University of California, School of Dentistry, 63-078 CHS
Su, Ding-Feng, Second Military Medical University, Dept of Pharmacology
Swanson, Geoffrey, University of Texas Medical Branch, Dept of Pharmacology & Toxicology
Tu, Yaping, Creighton University School of Medicine, Dept of Pharmacology
Wise, John, University of Southern Maine, Ctr for Integrated and Applied Env Tox
Wu, Jie, Barrow Neurological Institute, Neurology Research, Rm 444
Yun, June, Northeastern Ohio Univ School of Med, Dept of Physiology and Pharmacology
Zhang, Shuxin, Cubist Pharmaceuticals, Inc., Dept of Pharmacology
Zhao, Shouxun, Mount Sinai School of Medicine, Box 1247

AFFILIATE MEMBERS

Husain Taqvi, Syed, Jinnah Medical and Dental College, Dept of Pharmacology
Madhi Reddy, Ravi, Windsor University School of Medicine, Dept of Clinical Medicine
Philip, Binu, University of Louisiana, Dept of Toxicology
NEW MEMBERS, cont.

GRADUATE STUDENT MEMBERS

Ahmed, Sagheer, Aga Khan University, Dept of Biological & Biomedical Sciences
Al-Rejaie, Salim, East Carolina Univ Brody School of Med, Dept of Pharmacology & Toxicology
Anko, Minna-Liisa, Abo Akademi, Dept of Biology
Babu, K., 46 Narayana Nagar, Second Cross
Bhave, Vishakha, University of Louisiana, Dept of Toxicology
Booth, Erin, University of Michigan, Dept of Pharmacology
Brahmbhatt, Sachin, North Dakota State University, Dept of Pharmacology
Butterick, Tammy, University of Minnesota, Dept of Pharmacology
Chen, Chi, Rutgers University, Dept of Pharmaceutics
Collins, Gregory, University of Michigan Medical School, Dept of Molecular and Cellular Physiology
Damato, Ferdinando, Northeastern University, Dept of Chemistry
Dey, Surajit, University of Missouri, Dept of Pharmaceutical Sciences
Dudekula, Noor, University of Houston, Dept of Pharmacology
Fatokun, Amos, University of Glasgow, Div of Neuroscience & Biomedical Systems
Frost, Heather, Drexel University School of Medicine, Dept of Pharmacology and Physiology
Gabriele, Joseph, McMaster University, Dept of Neuropharmacology
Garcia Pacomeque, Jesus, University of Seville, Dept of Pharmacology
Gerber, Lamar, University of Cincinnati College of Medicine, Dept of Pharmacology & Cell Biophysics
Gilmore, Deborah, University of Oklahoma, HSC, Dept of Pharm Science
Golembewski, Erin, University of Maryland, Dept of Pharmacology
Hamad, Bashar, Coventry University, Cardiovascular Rsch Group
Hamadmad, Sumaya, University of Iowa, Carver College of Medicine
Horton, David, Transylvania University, Dept of Biology
Kalke, Nupoor, Loyola University, Dept of Pharmacology
Kim, Gunhee, University of Iowa, Dept of Pharmacology
Kinsey, Gilbert, Medical University of South Carolina, Dept of Pharmaceutical Sciences
Klein, Irene, University of Illinois, Dept of Pharmacology
Kota, Murali, Andhra University, School of Pharmaceutical Sciences
Lacroix-Fralish, Michael, Dartmouth University, Dept of Pharmacology and Toxicology
Lauver, D., University of Michigan, Dept of Pharmacology
Levy, Arkene, University of the West Indies, Dept of Basic Medical Science
Li, Jian, University of Louisville, Dept of Pharmacology & Toxicology
Mangu, Anand, University of Arkansas Medical Sciences, Dept of Pharmaceutical Sciences
Mantella, Rose, University of Pittsburgh, Dept of Pharmaceutical Sciences
Mickiewicz, Amanda, Loyola University Medical Center, Dept of Neuropharmacology
Misiuta, Iwona, University of South Florida, Dept of Pharmacology & Medical Sciences
Mitra, Mayurranjan, University of Louisville, Dept of Toxicology
Modi, Ketan, Shri B.M. Shah College of Pharmacy, Education and Research
Moodie-Henry, Bridgette, University of the West Indies, Dept of Basic Medical Sciences
Myers, Regina, Vanderbilt University, Dept of Pharmacology
Oden, Sherry, Wake Forest University School of Medicine, Hypertension Center
Palkar, Prajakta, University of Louisiana, Dept of Toxicology
Pearson, Rebecca, Georgetown University, Dept of Pharmacology
Polito, Anthony, Wright State University, Dept of Pharmacology & Toxicology
Pondugula, Satyanarayana, Kansas State University, Dept of Anatomy and Physiology
Pulido, Marisa, Texas A&M University HSC, Dept of Med Pharmacology & Toxicology
Purdham, Daniel, University of Western Ontario, Dept of Pharmacology
Rajesan, Ratheishan, University of Toronto, Div of Clinical Pharmacology & Toxicology
Reddy, Chinthaparthi, Sri Ramachandra Medical College, Dept of Pharmacology
Reece, Kelie, Vanderbilt University School of Medicine, Dept of Pharmacology
Shaik, Zabeena, University of Arkansas Medical School, Dept of Pharmaceutical Sciences
NEW MEMBERS, cont.

Shen, Fei, Loyola University Medical Center, Dept of Neuropharmacology
Silver, Christina, University of Maryland, Dept of Pharmacology
Strakova, Nicol, Palacky University, Laboratory of Molecular Pathology
Tawfik, Huda, East Carolina University, Dept of Pharmacology
Thakare, Mohan, Virginia Polytechnic Inst., Dept of Animal and Poultry Science
Williams, Yolanda, University of Kentucky, Dept of Pharmacology
Wu, Yong, Wuhan University College of Medicine, Dept of Pathophysiology
Zeiger, Fred, Florida International University, Dept of Bio-Chem
Zhang, Yi, University of Tennessee HSC, Dept of Pharmacology

UNDERGRADUATE STUDENT MEMBERS

Babatunde, Ebenezer, University of Lagos, Dept of Pharmacology
Brown, Edward, Temple University School of Pharmacy, Dept of Pharmaceutical Sciences
Elkordy, Shahenda, Brooklyn College, Dept of Chemistry
Harris, Whitney, Stanford University, Dept of Human Biology
Horvath, Bela, Semmelweis University, Dept of Pharmacology
Kane, Amber, SUNY, Dept of Biochemical Pharmacology
Patton, Carla, Lipscomb University, Dept of Biochemistry
Thomas, Ryan, Marist College, Dept of Chemistry

Contributors in 2004

<table>
<thead>
<tr>
<th>B.B. Brodie Award</th>
<th>Keith F. Killam, Jr.</th>
<th>Sustaining Members</th>
<th>Members Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Cashman</td>
<td>Theodore M. Brody</td>
<td>Craig Beeson</td>
<td>Elaine Sanders-Bush</td>
</tr>
<tr>
<td>Betty Sue Masters</td>
<td>John Bunker</td>
<td>Thomas Blaszkowski</td>
<td>George Van Rossum</td>
</tr>
<tr>
<td>Mary Vore</td>
<td>Kelvin Gee</td>
<td>Theresa Branchek</td>
<td></td>
</tr>
<tr>
<td>Alice Young</td>
<td>John P. Perkins</td>
<td>Henry J. Bryant</td>
<td></td>
</tr>
<tr>
<td>David Clarke</td>
<td>Barton Kamen</td>
<td>Hugh Burford</td>
<td></td>
</tr>
<tr>
<td>Theodore M. Brody</td>
<td>Theodore M. Brody</td>
<td>Stewart Ehrreich</td>
<td></td>
</tr>
<tr>
<td>Donald Franz</td>
<td>Donald R. Mattison</td>
<td>Jeffrey Fedan</td>
<td></td>
</tr>
<tr>
<td>A.E. Takemori</td>
<td>John McCullough</td>
<td>Gerald Gianutsos</td>
<td></td>
</tr>
<tr>
<td>Michael Ahlijianan</td>
<td>Raymond Novak</td>
<td>Giancarlo Guideri</td>
<td></td>
</tr>
<tr>
<td>Theodore M. Brody</td>
<td>Mark Perrone</td>
<td>Donald R. Mattison</td>
<td></td>
</tr>
<tr>
<td>Mark A. Osinski</td>
<td>Markus Peter</td>
<td>John McCullough</td>
<td></td>
</tr>
<tr>
<td>Mark M. Voigt</td>
<td>Walter Prozialeck</td>
<td>Raymond Novak</td>
<td></td>
</tr>
<tr>
<td>Kenneth D. Wild</td>
<td>Ralph Purdy</td>
<td>Mark Perrone</td>
<td></td>
</tr>
<tr>
<td>Paula Witt-Enderby</td>
<td>Paula Stern</td>
<td>Markus Peter</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Richard Vulliet</td>
<td>Walter Prozialeck</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Francis White</td>
<td>Ralph Purdy</td>
<td></td>
</tr>
</tbody>
</table>

Corporate Contributions

Thank you to our Corporate Associates

- Corporate Associate - Johnson & Johnson
- Corporate Benefactor – Merck & Company
David W. Robertson, Ph.D.
1955 – 2003

With deep sadness we report that our dear colleague and friend, Dr. David Wayne Robertson, died August 16, 2003, at his home in Ann Arbor, Michigan. Dave was born July 30, 1955, in Dumas, Texas, and is survived by two children, Cassandra and Andrew, of San Diego; his parents, R.L. and Nixie Robertson of Dumas; three sisters, Linda Hamlin of Mount Pulaski, IL, Glenna Rummel of Fritch, TX, Suzanne Roberts of Sumter, S.C.; and a brother, Timothy Robertson of Dumas. His funeral service was held at his hometown, Dumas, Texas, on August 22, 2003. At the time of death he was Executive Director of Central Nervous System and Cardiovascular Chemistry for Pfizer Pharmaceuticals.

Dr. Robertson earned his Bachelor of Science degree in Chemistry and Biology with highest honors from Stephen F. Austin State University in 1977, and his Master’s (1978) and Doctoral (1981) degrees in Bio-Organic Chemistry under the tutelage of Professor J.A. Katzenellenbogen at the University of Illinois (Research Thesis: 1. The Synthesis and Metabolism of Non-Steroidal Antiestrogens and Estrogens; and 2. Receptor Mediated Cytotoxicity: The Design and Synthesis of Cytotoxic Hormone Analogs).

Dr. Robertson joined Eli Lilly and Company as Senior Medicinal Chemist in 1981. He quickly engaged in drug discovery research, working with cardiovascular pharmacologists including Marlene L. Cohen, J. Scott Hayes, Don R. Holland, Ray F. Kauffman, Mitchell I. Steinberg and others on cardiotonic agents and vasodialators. Simultaneously he collaborated with neuropharmacologists including Ray W. Fuller, Donald R. Gehlert, J. David Leander, David T. Wong and others on anticonvulsants and antidepressants. Dave quickly advanced through the scientific rank to Senior Research Scientist and Research Group Leader in 1989, and in 1991 to administrative rank of Head & Director, Central Nervous System (CNS) and Endocrinology Research as well as Chairman of the CNS Strategy Group in the Lilly Research Laboratories.

Dave was recruited to Ligand Pharmaceuticals in San Diego, CA, where he served as a Vice President of Research from 1991 to 1996. He moved to DuPont Merck Pharmaceutical Co. in 1996, and to Pharmacia & Upjohn (Pharmacia Corp.) in 1999, where he was Vice President of Research. From 2002 until his death, Dave was Executive Director of Chemistry at Pfizer’s Ann Arbor, Michigan site.

Dr. Robertson had an exceptionally productive career. He contributed to the invention and discovery of more than 40 drug candidates that advanced to formation of Project Teams. Within two years of arriving at Lilly, Dave had a cardiovascular agent – Isomazole - in the clinic. Most notably, Dave was an inventor and adiscoverer of a selective serotonin uptake inhibitor, dapoxetine, and a dual inhibitor of serotonin and norepinephrine uptake, duloxetine. Phase III clinical studies of duloxetine have been completed, and Lilly has received approvable status of duloxetine for the treatment of depression under the trade name Cymbalta. His scientific accomplishments will benefit millions of patients.

Dave was one of those select medicinal chemists who showed great appreciation and understanding for biology and deep respect for practitioners of biological research. It was an uplifting experience to work with Dave. As a biologist one could expect weekly visits from Dave to discuss progress or recent scientific findings. Often he arrived with a vial of his latest chemical creation that would answer key questions in structure-activity studies. Besides engaging in the synthesis of molecules targeted for various projects, he also provided molecules that enabled colleagues to probe biological mechanisms. For the monoamine uptake inhibitor program, Dave and his able associates, Edward E. Beedle, Joseph Krushinski and Dennis Thompson, were instrumental in the custom synthesis of radioligands including [3H]-fluoxetine, [3H]-nisoxetine and [3H]-atomoxetine and others, too numerous to mention.

In addition to his own personal accomplishments, Dave excelled in building teams by putting together outstanding scientists and fostering their personal and team growth. It was only after his death that many of us realized Dave had unselfishly worked his magic in this respect for many pharmaceutical and biotechnology companies by putting the right people in contact with each other. His legacy is undoubtedly alive in the many colleagues and collaborators he has had over the years.

Dr. Robertson authored more than 120 publications, made over 145 presentations at scientific conferences and was an inventor on more than 60 U.S. patents. He was active in the American Chemical Society, a member of its Editorial Board, and Section Editor for Annual Reports in Medicinal Chemistry. In the Society of Pharmacology and Experimental Therapeutics, Dave served on the Finance Committee.
At Dave’s memorial service in Dumas, his colleagues learned that he was a scholar of the Bible, and was active in the ministry during his undergraduate and graduate student days. He faithfully practiced “Nothing is impossible” and the belief of a positive attitude in all pursuits. Dave was described as a “people person,” “mentor,” “friend” and a “great father.” He touched the lives of his colleagues and friends, who will remember him for many years to come.

The family suggests memorials be made in Dave’s name to the American Heart Association, 6605 W. Interstate 40, Building A6, Amarillo, TX 79106; the American Stroke Association at the above address; or the David Robertson Chemistry Scholarship Fund in care of Stephen F. Austin State University Alumni Association, P.O. Box 6096, Nacogdoches, TX.

Prepared by David T. Wong, Donald R. Gehlert, and J. Scott Hayes

Gilbert J. Mannering, Ph.D.
1917 – 2004

Gilbert Mannering, Professor of Pharmacology at the University of Minnesota from 1962 to 1987, died of natural causes, March 20, 2004. A man of seemingly endless energy (he toured the Amazon basin at the age of 83!) and an unbridled zest for life, he was one of the fortunate few who enjoyed an extraordinarily hardy constitution and was rarely, if ever, ill until late in life when he was diagnosed with type 2 diabetes, and very late in life when he endured vascular dementia. Professor Mannering had been a regular/emeritus member of the American Society of Pharmacology and Experimental Therapeutics since 1956. A memorial service celebrating his life was held on April 3, 2004, at the University Club (his favorite local haunt), St. Paul, Minnesota.

Born March 9, 1917, in Racine, Wisconsin, Gilbert J. Mannering was a graduate of Horlick (of malted milk fame) High School, Racine, where he was an active participant in chorus and track. He went on to earn B.S., M.S. and Ph.D. degrees, all in biochemistry and all from the University of Wisconsin, Madison, in 1940, 1943 and 1944, respectively. His M.S. and Ph.D. advisor was Professor Conrad A. Elvehjem, discoverer of niacin, and later, Lasker Awardee (1952) and president of the University (1958-1962).

Upon receiving his doctorate degree, the newly minted Dr. Mannering joined Parke-Davis and Company’s Vitamin Research Laboratory in Detroit, Michigan where he was employed as a Senior Research Bioc hemist from mid-1944 to early 1950. He then spent four years as a civilian scientist (consultant to the Chemistry Department, Civilian 406th Medical General Laboratory) for the United States Army in Tokyo, Japan from 1950 to early 1954.

Rejecting an offer to head the Department of Nutrition at the American University in Lebanon, Dr. Mannering then returned to his alma mater, serving briefly (only until mid-1954) as a Research Associate, then as an Assistant Professor of Pharmacology and Toxicology until mid-1958, and finally as an Associate Professor of Pharmacology and Toxicology until September, 1962. During this time, Professor Mannering served the Wisconsin State Crime Laboratory as a consultant with special expertise in toxicology.

In September 1962, Dr. Frederick Shideman, then chairman of the Department of Pharmacology and Toxicology, University of Wisconsin Medical School, accepted a similar position at the University of Minnesota and took almost all of the department’s faculty, including promoted-to-full Professor Mannering, and graduate and post-doctoral students with him. Upon retirement in 1987, Professor Mannering assumed the title of Professor Emeritus of Pharmacology, a position that he held almost to the end of his life.

First at Wisconsin and then at Minnesota, Professor Mannering went on to become one of the pioneers in fields of drug metabolism and biochemical toxicology. Despite becoming an academician when he was already 37 years old, at which time he had co-authored a mere ten primary research papers, he ended up authoring or co-authoring a total of over 125 primary research papers and over 25 reviews. He gave invited lectures at more than 40 American universities and in at least 20 countries. In collaboration with his colleagues, his observations led to the discovery of numerous ‘firsts’ in these fields. For example, his laboratory was one of the first, if not the first, to recognize and demonstrate the importance of measuring initial rates when quantifying in vitro rates of drug metabolism and kinetic constants thereof [J. Pharmacol. Exp. Ther. 123:171-179, 1958; J. Pharmacol. Exp. Ther. 127:187-190, 1959; Biochem. Pharmacol. 13:1007-1016, 1964], and his laboratory provided the first physical evidence for the existence of more than one drug-metabolizing cytochrome P450 [Biochem. Biophys. Res. Comm. 24:668-674, 1966].
In recognition of his many accomplishments, Professor Mannering was the recipient of many awards. Perhaps most notable, he was one of the early (4th) recipients of the Bernard B. Brodie Award in Drug Metabolism presented biennially by the American Society of Pharmacology and Experimental Therapeutics to “recognize outstanding original research contributions in drug metabolism and disposition, particularly those having a major impact on future research in the field.”

Professor Mannering was most proud of his work with, and the subsequent accomplishments of, his 22 graduate students (18 Ph.D. & 4 M.S.) and 19 postdoctoral fellows, many of whom followed in his academic footsteps and distinguished themselves as scholars in their own right. Included are one who received the Bernard B. Brodie Award in Drug Metabolism (Anders, 1999); two who received the John J. Abel Award in Pharmacology presented annually by the American Society of Pharmacology and Experimental Therapeutics “for original, outstanding research in he field of pharmacology and/or experimental therapeutics” by an individual who has not passed their thirty-ninth birthday on April 30th of the year of the Award (Schanker, 1966; Tephly, 1971); one who served as President of the American Society of Pharmacology and Experimental Therapeutics (Takemori, 1992); and at least seven who went on to become heads/chairs of academic departments in this (Schanker, Tephly, Anders, Shoeman) and other (Cohen, Sitar, Renton) countries.

Professor Mannering had hundreds of ideas, sometimes all in one day! He would arrive at the laboratory in the morning brimming with ideas and begin to rattle off experiments to be done. Some were technically impossible. Others had already been pursued. The trick for a graduate student, postdoctoral fellow or technician was to correctly identify the one or two out of the hundred that were most worthwhile pursuing, not an easy task, especially for newcomers to his lab!

Perhaps fittingly in view of his well-known fondness for malt beverages, the last of Professor Mannering’s primary research papers (Xenobiotica 26:487-493, 1996) dealt with murine cytochrome P4503A activity induced by a metabolite of colupulone, a constituent of hops. Providing a hugely enlightening summation of Professor Mannering’s professional life is an abbreviated autobiography published in Drug Metabolism Reviews 33:81-116, 2001 and entitled “A life in science: biochemist-nutritionist-forensic toxicologist-pharmacologist.”

Professor Mannering was very widely traveled, a talented photographer, an avid gardener, an opera buff and an ardent fan of the Gopher (University of Minnesota) basketball (men’s) and football teams as well as of the Minnesota Vikings (professional football). Further, he was extremely competitive whether the “competition” was in ping-pong, fishing or golf, a sport that he dearly loved even though he was not particularly good at it – once or twice a round, however, he would get off a magnificent shot, usually a drive, and that was enough to keep the ‘dream’ alive. He liked to begin golfing just after daybreak, largely because he hated waiting around while a group in front of him dawdled over a shot – to say that he was hugely impatient would be to understate the case! Another reason why he began golfing just after daybreak was that by doing so he could complete a full round of 18 holes and still be in his office by 8:00 a.m. His golf clubs almost always accompanied him on his many trips to other states and countries, and even though he usually was heavily committed to the business at hand time-wise, he would somehow manage to squeeze in a round or two of golf with like-minded colleagues. At home, “The Chief” often golfed alone (it’s difficult to find others that enjoy teeing off at daybreak!), almost always on the University of Minnesota Golf Course, a mature facility that favors precision more than length.

An accomplished raconteur with a robust sense of humor, Professor Mannering very much liked to play practical jokes and to tell stories, albeit often the same story more than once to a given audience! Telling him a story was another matter because he was never listening – he was always too engrossed in formulating the next story that he wanted to tell!

“Life is best played without a script” [Anonymous] was the mantra that Professor Mannering enthusiastically embraced throughout his long life. It served him well.

Professor Mannering is survived by son Michael; daughters Gail (Mrs. Doug) Beckman and Barb (Mrs. Greg) Hedlund; three grandchildren; four step-children; five step-grandchildren; and sister Carol (Mrs. Paul) Nielsen. He was preceded in death by his father John, born in England; mother Louise, of Danish descent; first wife Virginia in 1967; second wife Blanche in 1999; and brother John.

Prepared by N. E. Sládek

ASPET mourns the death on June 13, 2004, of our Secretary/Treasurer, Cinda J. Helke.
Chapter News

Mid-Atlantic Pharmacology Society
2004 Meeting

October 15, 2004
Wyeth Research
Collegeville, PA

8:00-8:45 Registration, Poster set-up
8:50 Welcome
Hugo M. Vargas, PhD, President, Mid-Atlantic Pharmacology Society
Steven Adelman, PhD, Wyeth, MAPS Conference organizer
9:00-9:45 Arthur Feldman, MD, PhD, Chairman, Dept of Medicine-Jefferson Medical College
"Immune Mechanisms in Heart Failure"
9:45-10:30 Myron Cybulsky, MD, University of Toronto, Toronto General Research Institute
"Initiation of Atherosclerosis: Endothelial Cell Gene Expression and Monocyte Recruitment"
10:30-11:00 Break
11:00-11:30 Douglas Harnish, PhD, Wyeth Research
"Nuclear Receptors in Cardiovascular Disease: Regulation of NFkB, the Immune Response and Atherosclerosis"
11:30-11:45 Greetings from Robert R. Ruffolo, Jr., PhD, President, Wyeth Research
11:45-12:45 Buffet Lunch, Poster (Judging)
12:45-1:45 Buffet Lunch, Poster Viewing, Graduate Student Workshop
1:45-2:45 Keynote lecture-
Donald Orlic, PhD., Hematopoiesis Section, Genetics and Molecular Biology Branch, NHGRI/NIH
"Stem Cells and Tissue Repair: State-of-the-Art"
2:45-3:00 Koelle Award
3:15-5:00 Poster Awards and Reception

For meeting information, contact:
Jeanne Coughlin (215-707-5227) or Hugo M. Vargas, PhD (215-652-8829)

New England Pharmacologists Becomes Newest ASPET Regional Chapter Affiliate

At its recent meeting, the ASPET Council approved the application from the New England Pharmacologists to become ASPET's fourth and newest regional Chapter Affiliate. The New England Pharmacologists have been meeting annually in January or February since 1972 to bring together the departments of pharmacology for the New England region. The meeting is student oriented with the goal of allowing students and postdocs to present their posters prior to the Experimental Biology meeting in the spring. The primary mission of the New England Pharmacologists is to foster education on pharmacology and interactions between pharmacologists in the New England region.

The current President of the Chapter is Dr. David J. Mokler, and the current Secretary/Treasurer is Dr. Edward Bilsky, both of the University of New England College of Osteopathic Medicine. For information on NEP, contact Dr. Mokler (dmokler@une.edu) or Dr. Bilsky (ebilsky@une.edu).
Definitions of Categories of ASPET Membership

**Regular Members:** "Any qualified investigator who has conducted and published a meritorious original investigation in pharmacology shall be eligible for membership in the Society." - Bylaws Article II, Section 1, Item 1. An individual who holds an earned doctoral degree (Ph.D., M.D., or equivalent) is considered a qualified investigator. (Exceptions may be made for someone who does not meet the degree requirement but who has made major original research contributions to pharmacology.)

**Affiliate Members:** "Any qualified person who is engaged in the study of problems in pharmacology but does not meet the requirements for Regular Membership may be eligible for Affiliate Membership, which shall be nonvoting. Affiliate members may later be proposed for Regular Membership, upon meeting the requirements.” - Bylaws Article II, Section 1, Item 5. Affiliate Members include representatives in the following careers: faculty members who have made their contribution in teaching; productive research team members who have not published a meritorious original publication; and administrators in government, industry, universities, or other organizations who do not have sufficient independent research to qualify for Regular membership.

**Student Members:** “Persons who are enrolled in undergraduate, graduate, or professional degree programs, and who have an interest in pharmacology, are eligible for Student membership, which shall be non-voting. Student members may be proposed later for Regular Membership or Affiliate Membership upon meeting the requirements for that membership category. Upon completion of their research doctoral degree, applicants are normally eligible for Regular Membership but may remain in the Student Member category for no more than two (2) years.” - Bylaws Article II, Section 1, Item 6.

**Regular Members** (Dues $105):
- Receive *Molecular Interventions* and *The Pharmacologist*.
- Have free online access to all of ASPET’s journals.
- May subscribe to print versions of Society publications at reduced member rates.
- Pay half-price page charge rates ($30/page) and color figure fees ($200/figure) in Society journals.
- Receive a free copy of the *FASEB Newsletter*.
- Present independent papers at all Society meetings.
- Sponsor a paper for a non-member at all Society meetings.
- Nominate candidates for membership.
- Vote on all Society ballots and may hold elected office in the Society.
- Have access to the members only portion of the ASPET Web site (www.aspet.org)
- Are listed in the FASEB print and on-line directory.

**Affiliate Members** (Dues $90) have all the benefits of Regular Members except they may:
- Sponsor candidates for Student membership only.
- Not sponsor a paper for a non-member at a Society meeting.
- Not vote in Society elections.
- Not hold an elected office in the Society.

**Student Members** (Dues $25) have all the benefits of Regular Members except they:
- Pay no dues their first year.
- Pay only 25% of the Regular Member dues rate thereafter.
- Must have their papers at Society meetings sponsored by a member.
- May not vote in Society elections nor hold an elected office in the Society except for office in the Student Chapter of ASPET.

### 2004 Publication Subscription Rates for Members

All Society Members qualify for the following reduced publication subscription rates:
- *Journal of Pharmacology and Experimental Therapeutics* (Monthly) - $156/year
- *Pharmacological Reviews* (Quarterly) - $66/year
- *Drug Metabolism and Disposition* (Monthly) - $78/year
- *Molecular Pharmacology* (Monthly) - $102/year
- *Clinical Pharmacology and Therapeutics* (Monthly) - $38/year, $70/year for Canada/Foreign
- *Molecular Interventions* (Bimonthly) – included with dues

### Application Instructions and Suggestions
Submit a typed original and one (1) copy of the completed Application for Membership form or use the online application form on the ASPET web site at [http://www.aspet.org/membership](http://www.aspet.org/membership). Submit a current curriculum vitae including bibliography for Regular and Affiliate Membership. You may e-mail the CV.

### Sponsor Statements
Submit signed statement(s) of qualifications of the applicant from two Regular Members of ASPET for Regular Membership and from one Regular Member of ASPET for Affiliate Membership and Student Membership (Affiliate Members may also sponsor student applicants). In addition to statement certifying that the applicant is qualified for ASPET membership, sponsors please provide your own current address, phone, fax and email. **It is the responsibility of the applicant to secure these documents.**
Application for Membership
American Society for Pharmacology and Experimental Therapeutics
9650 Rockville Pike, Bethesda, Maryland 20814-3995 USA, Phone (301) 634-7060

Application for ( ) Regular, ( ) Affiliate, ( ) Graduate Student, or ( ) Undergraduate Student Membership
Year: ( ) Fresh, ( ) Soph, ( ) Jr, ( ) Sr

APPLICANT. Please complete this section – type if possible.

Name and Address: Telephone:

FAX:

E-mail:

Date of Birth:

Education and Training:

Professional Experience (Present position first) Include dates, position and organization.

Paperwork Summary: submit original and 1 copy of the following:
1. Application form.
2. Statement and signatures from two sponsors for Regular membership and from one sponsor for Affiliate/Student membership.*
3. Curriculum vitae (include bibliography) for Regular and Affiliate membership.

*A letter or e-mail may be sent by the sponsor to the Membership Coordinator (rphipps@aspet.org) in lieu of the sponsor’s signature and statement of qualifications of the applicant on the form. Call or e-mail the ASPET Membership Department for additional information: (301) 634-7135 / rphipps@aspet.org
For on-line submission, go to http://www.aspet.org/public/membership/memberapplform_ia_1003.pdf
II INTERNATIONAL CONGRESS OF PHARMACOLOGY AND THERAPEUTICS
V NATIONAL CONGRESS, CUBAN SOCIETY OF PHARMACOLOGY
II National Workshop on Pharmacological Surveillance

Latinoamerican School of Medicine, Havana, Cuba
OCTOBER 12th-15th, 2004

The Cuban Society of Pharmacology invites to participate in the II International Congress of Pharmacology and Therapeutics "Havana 2004" and V National Congress of Pharmacology, which will take place at the wonderful scenario of Havana, capital of the bigger island of the Antilles and place that mixes the modernity of a city in constant development with the welcoming and unforgettable colonial atmosphere. The beauty of their beaches, the green of their fields and the contagious happiness of the Cuban people, will live forever in the visitor’s memory. We expect you to join this unique opportunity to combine the exciting field of the pharmacological sciences with the cultural and historical treasures of Cuba and Havana City.

MAIN TOPICS AND OTHERS INFORMATION
http://cencomed.sld.cu/farmacologia/

Inscription fee (before agost 30th)
Delegates 200.00 USD Accompanying 60.00 USD Students 100.00 USD
After agost 30th, addition of 50 USD

Deadline for abstracts: July 15th, 2004
Contact to: Dr. René Delgado Hernández,
Tel: 537-217822, 217925, 271 5067 TeFax: 537-336471
E-mail: rdelgado@cqt.co.cu ó rdelgado@infomed.sld.cu

CUBATUR Events has designed a tourist package for the Congress
Please, contact to CUBATOUR SA OPC Arlene Alvarez Rey
Email: opc_eventos@cbtevent.cbt.tur.cu

Awaiting your distinguished presence in Pharmacology Congress Havana 2004!!
Future Meetings

Experimental Biology ‘05
San Diego, CA
Saturday-Wednesday
April 2-6, 2005
(AAA, AAI, APS, ASIP, ASBMB, ASNS, ASPET)

Experimental Biology ‘06
San Francisco, CA
Saturday-Wednesday
April 1-5, 2006
AAA, APS, ASIP, ASBMB, ASNS, ASPET

Experimental Biology ‘07
Washington, DC
Saturday-Wednesday
April 28-May 2, 2007
AAA, APS, ASIP, ASBMB, ASNS, ASPET